Fractyl Health (NASDAQ:GUTS) Given Buy Rating at Canaccord Genuity Group

Canaccord Genuity Group restated their buy rating on shares of Fractyl Health (NASDAQ:GUTS) in a research note released on Thursday morning,Benzinga reports. Canaccord Genuity Group currently has a $8.00 price target on the stock.

GUTS has been the subject of several other research reports. Morgan Stanley downgraded shares of Fractyl Health from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $8.00 to $2.00 in a report on Thursday, January 29th. HC Wainwright reiterated a “buy” rating and set a $8.00 price objective on shares of Fractyl Health in a research report on Tuesday, December 2nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Fractyl Health in a report on Monday, December 29th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $5.40.

Fractyl Health Trading Down 5.4%

NASDAQ:GUTS opened at $0.47 on Thursday. Fractyl Health has a 12-month low of $0.38 and a 12-month high of $3.03. The firm has a market capitalization of $75.07 million, a P/E ratio of -0.26 and a beta of 1.51. The company has a debt-to-equity ratio of 3.23, a current ratio of 4.78 and a quick ratio of 4.27. The business has a 50 day simple moving average of $0.73 and a 200 day simple moving average of $1.28.

Fractyl Health (NASDAQ:GUTS) last released its quarterly earnings results on Tuesday, March 24th. The company reported $0.15 EPS for the quarter, topping the consensus estimate of ($0.19) by $0.34. Equities research analysts predict that Fractyl Health will post -1.61 EPS for the current year.

Institutional Trading of Fractyl Health

Several large investors have recently added to or reduced their stakes in GUTS. Bank of America Corp DE boosted its holdings in Fractyl Health by 23.5% in the third quarter. Bank of America Corp DE now owns 88,634 shares of the company’s stock worth $141,000 after purchasing an additional 16,856 shares in the last quarter. Jane Street Group LLC bought a new stake in Fractyl Health during the 2nd quarter valued at approximately $31,000. FNY Investment Advisers LLC acquired a new stake in shares of Fractyl Health in the third quarter worth $31,000. Jump Financial LLC acquired a new stake in Fractyl Health in the 4th quarter worth $57,000. Finally, Scientech Research LLC acquired a new stake in Fractyl Health during the third quarter worth about $49,000.

More Fractyl Health News

Here are the key news stories impacting Fractyl Health this week:

• Positive Sentiment: Q4 2025 results and earnings-call takeaways showed better-than-expected results and operational color that investors liked — management highlighted the quarter and outlook that helped drive upside reaction. Earnings Call Highlights
• Positive Sentiment: Analysts moved more bullish: HC Wainwright raised FY2029–FY2030 EPS estimates and reiterated a Buy with an $8 price target; Canaccord also reaffirmed a Buy and $8 PT — both signals can attract momentum buying given the large implied upside vs. the current price. Analyst Notes (MarketBeat) Canaccord Note
• Positive Sentiment: Shares jumped sharply in after-hours trading (reported ~21% move) on the combination of the results, call and analyst commentary — a clear short-term bullish reaction. After-hours Coverage
• Neutral Sentiment: The full Q4 2025 earnings call transcript is available for investors who want the exact management comments; use it to judge sustainability of the upbeat guidance and timing of any commercial/clinical milestones. Call Transcript
• Neutral Sentiment: Macro and micro risks remain: the consensus for the current fiscal year is still a material loss (analyst consensus ~-1.61 EPS), the stock is low-priced with thin liquidity and is trading below its 50- and 200-day averages — factors that can amplify volatility but not necessarily change the fundamental reaction to positive news.
• Negative Sentiment: The company disclosed a new regulation/compliance risk tied to global anti‑corruption and sanctions laws — this raises potential legal/compliance costs and execution risk that could weigh on valuation if it leads to investigations, fines, or limits on international activity. Compliance Risk Notice

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.